Enavogliflozin, also known by the development code DWP16001, is a selective inhibitor of the sodium-glucose cotransporters SLC5A2 and SGLT2. It was developed by GC Pharma and Daewoong Pharmaceutical to treat diabetes and obesity. According to its encyclopedia article it has been approved for clinical use in South Korea and Ecuador, and approval applications have been made in Brazil, Mexico, Peru and Colombia. A meta-analysis of four trials over six months of clinical use found it well tolerated and effective for managing type 2 diabetes. This entry records what the source lead states and is not medical advice.
Facts
Classification
Approval Status ATC ClassA: Alimentary Tract and Metabolism 2 Connections
Treats
Source Enavogliflozin (Wikipedia)
Sources
1. Enavogliflozin (Wikipedia)
Lead paragraph
Enavogliflozin has been approved for clinical use in South Korea, and Ecuador
Treats: Diabetes Mellitus, Lead paragraph [treats]
developed to treat diabetes and obesity
View the Source2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATC/DDD Index entries named Enavogliflozin
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATC/DDD Index entry; ATC class derived from cited code A10BK09 (main group A)Quote, ATC/DDD Index entry; ATC class derived from cited code A10BK09 (main group A)
A10BK09 enavogliflozin
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.